The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

Guidelines recommend older adults with newly diagnosed AML should be offered antileukemic therapy over best supportive care.

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical ...

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...

Black patients are diagnosed with acute myeloid leukemia at a younger age and are more likely to die from the blood cancer, ...

An expert panel now recommends using certain personalized therapies in the frontline setting for older adults with FLT3- and IDH1-mutant disease.

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® (revumenib) was named Best New Drug at the ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high ...

Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range ...

Azacitidine plus venetoclax significantly improved multiple outcomes for certain patients with acute myeloid leukemia ...

Acute myeloid leukemia (AML) is a malignancy characterized by the clonal proliferation of myeloid hematopoietic progenitor or stem cells, primarily ...